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Abstract Human islet amyloid polypeptide (hIAPP), co-
secreted with insulin from pancreatic L cells, misfolds to form
amyloid deposits in non-insulin-dependent diabetes mellitus
(NIDDM). Like many amyloidogenic proteins, hIAPP is
membrane-active: this may be significant in the pathogenesis of
NIDDM. Non-fibrillar hIAPP induces electrical and physical
breakdown in planar lipid bilayers, and IAPP inserts sponta-
neously into lipid monolayers, markedly increasing their surface
area and producing Brewster angle microscopy reflectance
changes. Congo red inhibits these activities, and they are
completely arrested by rifampicin, despite continued amyloid
formation. Our results support the idea that non-fibrillar IAPP is
membrane-active, and may have implications for therapy and for
structural studies of membrane-active amyloid. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Many human and animal diseases, including Alzheimer’s
disease (AD) and non-insulin-dependent diabetes mellitus
(NIDDM), are characterised by the presence of ‘amyloid’ in
a¡ected tissues. Amyloid is composed of misfolded L-sheet
rich proteins that assemble spontaneously into proto¢brils
which subsequently form higher order structures, ranging
from simple twisted pairs of helical ¢brils to complex and
extensive sheets of protein [1]. Although di¡erent cellular pro-
teins misfold in particular diseases, for example neuronal AL
proteins in AD, and pancreatic L cell islet amyloid polypep-
tide (IAPP) in NIDDM, proto¢brils share a common struc-
ture that confers distinctive physical properties shared by all
amyloid deposits. These properties include diagnostic green
birefringence under crossed polarisers in the presence of the
histological stain Congo red, attributable to the characteristic
‘cross L’ structure of the ¢brils [2^4].
The amyloidogenic protein IAPP (also known as amylin), a
37 residue polypeptide hormone co-secreted with insulin, has
been directly implicated in the pathogenesis of NIDDM be-
cause (a) IAPP is normally soluble, and only misfolds and
aggregates in NIDDM, and (b) there is a strong correlation
between the ability of IAPPs from di¡erent mammals to form
amyloid, and susceptibility to NIDDM. For example, humans
and cats can develop NIDDM, and if they do, their IAPPs
form amyloid in and around pancreatic islet cells. Rat and
mouse IAPPs do not have an amyloidogenic motif [5,6] and
these animals do not develop NIDDM. Consistent with these
observations, recombinant human (h) IAPP is both amyloid-
ogenic and membrane-active in cells transfected with appro-
priate cDNAs, and mice expressing the hIAPP transgene can
develop a condition closely resembling NIDDM [7].
In vitro, hIAPP misfolds and aggregates spontaneously,
whereas in individuals with NIDDM, IAPP presumably only
misfolds after evading normal processing. The primary defect,
which may result from a combination of inherited and envi-
ronmental factors, remains to be discovered. In any case, mis-
folded IAPP is demonstrably toxic to cells. At the membrane
level, misfolded IAPP interacts with lipid bilayers to destabi-
lise them, and forms poorly selective cation-permeable ‘ion
channels’ [8]. In vivo, similar e¡ects could result in excessive
Ca2 entry and cell death, and increases in intracellular [Ca2]
secondary to the loss of plasma membrane integrity may be
augmented by the disruption of membrane-bound stores by
intracellular amyloid. The availability of multiple mecha-
nisms, with di¡erent rates and modes of Ca2 entry into the
cytoplasm, could help to explain why cells exposed to amy-
loidogenic IAPP die by both apoptosis and necrosis [9]. In
contrast, a non-aggregating form of IAPP (rat IAPP) does
not destabilise planar bilayers, and hIAPP that has been al-
lowed to develop ¢brils is also inert [9]. A similar observation
has been made concerning AL proteins [10]. The membrane
activity of IAPP thus appears to be related to the presence of
an early, transitory, molecular form [9], distinct from the ¢-
brillar IAPP found in mature amyloid.
The ‘toxicity’ of IAPP and AL proteins is reduced by rifam-
picin and related chemicals [11,12], and also by Congo red
[13,14]. In the present study, we show that rifampicin and
Congo red inhibit the membrane activity of freshly dissolved
non-¢brillar hIAPP, although the protein continues to aggre-
gate and form amyloid. In addition, we show that rifampicin
prevents membrane insertion of the peptide. Our results pro-
vide an independent test of the hypothesis that an early, non-
¢brillar form of IAPP is membrane-active [9]. We also provide
a method to arrest the membrane activity of IAPP before
irreversible membrane breakdown occurs. The use of similar
inhibitors may allow more detailed structural studies of the
molecular basis of the membrane activity of amyloid proteins,
and new ways to intervene in amyloid diseases.
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2. Materials and methods
2.1. Materials
hIAPP was synthesised by Bachem (St Helens, UK) and ResGen
(Huntsville, AL, USA). The peptide was stored desiccated at 320‡C.
Rifampicin was from Fluka (Poole, UK) and Congo red was obtained
from Sigma (Poole, UK). Freshly dissolved synthetic hIAPP was con-
¢rmed to be monomeric by light-scattering studies, as in previous
work [9], and we also con¢rmed the absence of ¢brils following neg-
ative staining and electron microscopy. Dimyristoyl-phosphatidylcho-
line (DMPC), palmitoyloleoyl-phosphatidylethanolamine (POPE) and
palmitoyloleoyl-phosphatidylserine (POPS) were purchased from
Avanti (Birmingham, AL, USA), and used without further puri¢ca-
tion.
2.2. Planar bilayer recording
Planar bilayers were cast across a 0.3 mm diameter hole in a poly-
styrene partition separating two solution-¢lled chambers. The experi-
ments were carried out at room temperature in 10 mM KCl bu¡ered
with 20 mM Tris^HCl (pH 7.4), using bilayers cast from equimolar
mixtures of POPE and POPS suspended in decane, as previously
described [9,15]. Bilayer currents were digitally recorded under volt-
age-clamp conditions using an Axopatch 200B ampli¢er (Axon, Fos-
ter City, CA, USA). All values for voltage and current were measured
with reference to the cis chamber, and the trans chamber was
grounded. Large, high-resistance bilayer membranes, with a capaci-
tance of at least 200 pF and a conductance less than 5 pS (i.e. less
than 25 pS/nF), were observed for 14 min before use, to verify that
they were electrically stable. IAPP was added to the bilayers by stir-
ring small aliquots (V1% (v/v)) of freshly dissolved concentrated so-
lutions into the cis chamber, using a magnetic stirrer. Salt concentra-
tions were altered by additions from concentrated stock solutions, or
by perfusion (10 volumes). Inhibitors were added as small (V1%
(v/v)) aliquots of concentrated stock solutions (up to 20 mM), as
described in Section 3.
2.3. Langmuir ¢lms
Lipid monolayers were assembled using a Langmuir ¢lm balance
(NIMA Technology, Coventry, UK) with a surface pressure feedback
system to measure the area per lipid molecule (i.e. monolayer expan-
sion or contraction) at constant surface pressure. IAPP and inhibitors
were added to the subphase as required. A pure water isotherm was
recorded before each experiment to con¢rm the absence of residual
surface impurities. Lipids were then deposited directly onto the sur-
face from chloroform dispersions, with the trough barrier open to its
maximum position. The solvent was allowed to evaporate unper-
turbed for 15 min, and a further compression isotherm was recorded
to verify that the lipid monolayer remained free from impurities.
Typically, no more than 30 Wg of lipid was used to form the mono-
layer, in order to restrict the ¢nal surface area to no more than 20^
25% of the maximum area available (V200 cm2). This allowed for
any expansion following incorporation of the peptide. The surface
pressure was then set to 18^20 mN/m, to provide an area of 65 Aî 2
per molecule of pure lipid. After constructing a lipid monolayer, IAPP
was dissolved in puri¢ed water and immediately transferred to the
subphase by pipetting the solution underneath the trough barrier, to
provide a ¢nal subphase concentration of 5 WM. The barrier move-
ment was programmed to maintain the initial surface pressure, and we
recorded any changes in surface area. In experiments with inhibitors,
we added the same (5 WM) concentrations of Congo red or rifampi-
cin to the subphase. The area of each monolayer was monitored for
1^4 h.
2.4. Brewster angle microscopy (BAM) and polarised light microscopy
A microscope with laser optics (Nano¢lm Technologie, Go«ttingen,
Germany) was assembled near the microbalance (compressed) end of
the Langmuir trough to monitor re£ection from the Langmuir ¢lm
[16]. A PC-controlled 10U video recorded any changes including
monolayer-associated aggregates or other interesting features. Because
such features were spread non-uniformly across the surface, at the
conclusion of each experiment we closed the trough barrier to bring
any features into the ¢eld of view of the microscope. Green birefrin-
gence of IAPP samples following the formation of amyloid in the
presence or absence of inhibitors was observed in the presence of
Congo red using a conventional light microscope equipped with
crossed polarising ¢lters.
3. Results
3.1. Inhibition of IAPP activity in bilayers
Low ionic strength solutions enhance the interaction of
IAPP with membranes [8,9], and bilayers were cast in 10
mM KCl containing 20 mM Tris^HCl (pH 7.4) to maximise
the e¡ect of IAPP and conserve material. Initially, freshly
dissolved IAPP (known to be non-¢brillar, see Section 2)
was added to a ¢nal concentration of 2 WM to the cis side
of bilayer membranes that had been shown to be stable for 14
min. IAPP induced a signi¢cant increase in membrane con-
ductance when this was re-measured 5 min later (Fig. 1, open
bar).
‘Channel-like’ activity was often visible at early stages of
this process, as previously observed [8]. The ‘channel-like’
activity was more easily visualised by increasing the concen-
tration of the permeant salt to 250 mM (not shown), but the
putative channels did not always exhibit well-de¢ned unit con-
ductances, and could not be distinguished from the non-spe-
ci¢c electrical leak also known to be induced by the peptide
[9]. We therefore calculated macroscopic bilayer conductan-
ces, normalised to the bilayer area (i.e. to the bilayer capaci-
tance), and did not attempt to distinguish between ‘ion chan-
nels’ and less well-de¢ned membrane leakiness. As previously
reported [9], ¢brillar IAPP was ine¡ective. More prolonged
exposure to freshly dissolved IAPP (up to V15 min) resulted
in bilayer instability and breakage (also as previously reported
[9]).
The conductance of bilayers exposed to 2 WM freshly dis-
solved, monomeric [9] IAPP was signi¢cantly reduced in the
presence of 10 WM rifampicin or 10 WM Congo red (Fig. 1,
shaded bars). Rifampicin was more e¡ective than Congo red,
and the membrane activity of 5 WM IAPP was reduced in a
dose-dependent manner in the presence of rifampicin (Fig. 2),
with half-maximal inhibition by 2.9 WM. To determine
whether rifampicin could a¡ect the interaction of IAPP with
membranes once it had been initiated, 10 WM rifampicin, or
vehicle alone (DMSO), was added to membranes 5 min after
adding 2 WM IAPP. Before adding the inhibitor, the mem-
Fig. 1. Rifampicin and Congo red inhibit the membrane activity of
IAPP. Planar bilayers that had been stable for 14 min were exposed
to 2 WM IAPP by stirring a freshly prepared concentrated solution
of the peptide into the cis chamber for 1 min. Membrane conduc-
tance and capacitance were measured after a further 5 min for con-
trol, non-inhibitor treated membranes (open bar), and for mem-
branes exposed to 10 WM rifampicin (black bar) or 10 WM Congo
red (grey bar). Data are shown þ S.D. for four to six independent
experiments (*** indicates P6 0.001 by t-testing for signi¢cant dif-
ferences from the control).
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brane conductance was found to increase with time following
IAPP addition, and all the membranes became unstable and
broke within 15 min. After the addition of rifampicin, mem-
brane conductances remained elevated, without any evidence
that the e¡ect of IAPP was reversed. However, these mem-
branes were ‘stabilised’, so that their conductance no longer
increased with time, and bilayer lifetimes were increased (Fig.
3).
3.2. Inhibition of IAPP activity in monolayers
There are many possible mechanisms by which rifampicin
and Congo red could inhibit the membrane activity of IAPP.
To investigate the mechanisms in more detail, we constructed
classical monocomponent monolayers containing only
DMPC, and monolayers containing 1:1 molar mixtures of
POPE and POPS, as used for the bilayer experiments. The
monolayers were exposed to freshly dissolved IAPP in the
presence and absence of inhibitors to determine whether the
compounds prevented membrane insertion of the peptide (Fig.
4). Following the injection of 5 WM IAPP into the subphase in
the absence of inhibitors, the area of the monolayer expanded
substantially with time. The rate of expansion was approxi-
mately hyperbolic (Fig. 4, upper trace), and expansion con-
tinued for at least 4 h (the maximum period of observation).
Control monolayers showed no change in surface area over
similar time periods (not shown).
In striking contrast, the surface area of monolayers exposed
to IAPP in the presence of 5 WM rifampicin failed to increase
(Fig. 4, lower trace), indicating that under these conditions the
peptide remained con¢ned to the subphase, and did not inter-
act with the lipid monolayer. The initial rate of IAPP-induced
increase in surface area was reduced when the subphase con-
tained 5 WM Congo red, but thereafter monolayer expansion
continued at about the same rate seen in IAPP-exposed mono-
layers. In the experiment shown in Fig. 4 (middle trace), the
monolayer expanded (over 60 min) to 93 Aî 2 per molecule of
pure lipid in the presence of Congo red, compared to 103 Aî 2
per molecule of pure lipid without inhibitor (itself representing
a 60% increase in area compared to control membranes). We
obtained similar results using DMPC monolayers (results not
shown).
Complementary BAM observations, making use of the
unique (Brewster) angle of incidence that just disallows sur-
face re£ections under control conditions, permitted highly
sensitive observations of optical changes at the monolayer/
subphase interface following the addition of IAPP [16]. We
observed pleomorphic changes as IAPP associated with
monolayers, including extensive, irregular surface-associated
structures containing regions of very bright re£ection (Fig.
5). Although monolayers exposed to IAPP in the presence
of Congo red also developed extensive surface-associated de-
posits of IAPP, none of these changes was seen in the presence
of rifampicin. Finally, we con¢rmed that IAPP pre- or post-
stained with Congo red formed birefringent aggregates typical
of amyloid deposits over the course of 24^48 h when viewed
under crossed polarisers (not shown), even when IAPP was
Fig. 2. Inhibition by rifampicin is concentration-dependent. Bilayers
formed 14 min earlier were exposed to 5 WM IAPP in the presence
of the indicated concentrations of rifampicin. Bars represent þ S.D.
of four to ¢ve independent experiments, and other points are aver-
ages of up to three experiments. The smooth curve is ¢tted to a sin-
gle-site inhibition model: conductance = maximum conductance/
(1+[rifampicin]/Ki), where Ki is 2.9 WM and maximum conduc-
tance = 850 pS/nF.
Fig. 3. Rifampicin ‘stabilises’ planar bilayers exposed to IAPP.
2 WM IAPP was added to bilayers that had been stable for after 14
min, and stirred in for 1 min. The membrane conductance was mea-
sured at intervals (open symbols) up to 25 min (i.e. 11 min after
IAPP addition). After this time, up to 50% of the bilayers broke. In
some experiments, 10 WM rifampicin was added 6 min after IAPP
(¢lled symbols). These bilayers remained intact, and measurements
were continued for a further 25 min without bilayer breakdown.
Bars indicate þ S.E.M. for three to ¢ve independent experiments.
Fig. 4. Inhibitors attenuate or arrest IAPP-induced monolayer ex-
pansion. Representative traces from three experiments recording
monolayer expansion (at constant surface pressure) after adding
5 WM IAPP to the subphase (arrow) in the absence of inhibitors
(upper trace, continuous line), in the presence of 5 WM Congo red
(middle trace, dotted line), and in the presence of 5 WM rifampi-
cin (lower trace, broken line). The monolayer contained equimolar
POPE:POPS. Similar results were obtained using DMPC (not shown).
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exposed to 5 WM of the inhibitors immediately from the outset
of solubilisation.
4. Discussion
Rifampicin prevented amyloidogenic, membrane-active
IAPP from increasing the conductance of planar lipid bi-
layers. Although Congo red was less protective (at the same
concentration), it also reduced membrane activity signi¢-
cantly. Rifampicin also ‘stabilised’ bilayer membranes, so
that membrane lifetimes were no longer markedly reduced
in the presence of the membrane-active peptide. However,
neither rifampicin nor Congo red prevented the time-depen-
dent assembly of IAPP into amyloid ¢brils showing diagnostic
green birefringence when stained with Congo red. Studies us-
ing lipid monolayers indicated that rifampicin prevents the
membrane incorporation of IAPP, but compared to rifampi-
cin, similar concentrations of Congo red only partially inhib-
ited the interaction of IAPP with both neutral and charged
monolayers.
Although IAPP [8] (and other amyloidogenic proteins, e.g.
AL [17]) have been shown to give rise to ‘channel-like’ activity
in bilayers, we did not observe well-de¢ned unit conductances
in the present study, suggesting that IAPP-related transmem-
brane ion channels may not have a consistent, well-de¢ned
molecular structure. Also, the formation of discrete ion chan-
nels cannot explain the membrane instability and breakage
associated with IAPP. In these respects, the membrane activ-
ity of IAPP resembles that of the soluble, apoptosis-related
proteins that induce pore formation in mitochondrial mem-
branes, especially Bax [18]. Basanez et al. [18] provided evi-
dence to support the idea that Bax-induced ion channels con-
tain intercalated lipid, helping to explain why Bax-mediated
pores enlarge uncontrollably beyond a certain critical diame-
ter. In addition to the uncertainties concerning the molecular
structure of membrane channels or leak pathways induced by
amyloidogenic membrane-active proteins, the mechanism by
which the proteins actually become incorporated into mem-
branes also remains unclear. We speculated that the inhibitors
might a¡ect the membrane insertion of IAPP, and we at-
tempted to gain insights into this and other aspects of the
membrane activity of IAPP by carrying out experiments in-
volving lipid monolayers (Langmuir ¢lms).
Despite very obvious structural di¡erences, lipid mono-
layers can nevertheless provide useful information about the
behaviour of lipid bilayers (the principle of equivalent states
[19]). IAPP inserted spontaneously into ultrathin lipid ¢lms,
inducing large increases in membrane surface area. Under the
experimental conditions we used, the surface area increased
up to two-fold over the course of V4 h, with much of this
increase taking place within the ¢rst 20 min of exposure to
IAPP. The rapid intercalation of protein on such a major
scale was unexpected, and would be predicted to lead to the
membrane disruption commonly observed in bilayers. Equi-
molar rifampicin completely prevented IAPP insertion, while
equimolar Congo red slowed the initial rate of incorporation
of IAPP into the monolayer. Using BAM, we observed ag-
gregates of IAPP in or just below the plane of the monolayer.
Aggregates were not formed in the presence of rifampicin,
suggesting that under the conditions used here, rifampicin
completely prevents any interaction between IAPP and the
membrane lipids.
Taken together, our results show that IAPP incorporates
spontaneously into membranes to form extensive higher order
structures. We speculate that the intensely bright regions fre-
quently seen in the IAPP aggregates under BAM represent
IAPP-enriched regions where the polypeptide has completely
traversed the monolayer to become surface-exposed. The in-
corporation of membrane-active L-sheet rich proteins into
membranes may be enhanced by electrostatic interactions
[20], and may be accompanied by a poorly understood struc-
tural transition giving rise to transmembrane K-helices [21^
23]. It is possible that such transmembrane helices could asso-
ciate to form water-¢lled ion channels. Results from mono-
layer studies clearly cannot be compared directly to bilayers
because of the absence of one lea£et of the bilayer, and also
because the behaviour of monolayers (especially those con-
taining more than one lipid species) is incompletely character-
ised [24]. However, monolayer studies appear to have the
potential to provide useful information concerning the inter-
action of IAPP with phospholipids, especially when combined
with studies in planar bilayers and experiments on living cells.
Some of our results concerning IAPP may also have impli-
cations for AD, where amyloid-containing plaques are com-
prised of 40^43 residue polypeptides (AL1^40, AL1^42 and
AL1^43) produced by proteolytic processing of amyloid pre-
cursor protein [25]. Although (as in NIDDM) there is clearly
a close relationship between amyloid production and the dis-
ease, in AD amyloid deposition is unlikely to be the primary
problem. Many other changes occur in AD, including changes
that appear to be entirely unrelated to AL1^42(3) production,
Fig. 5. IAPP-induced changes in membrane re£ection visualised by
BAM. Representative BAM images showing appearances at the
monolayer/water interface in control DMPC monolayers, which
showed no change in appearance with time, and monolayers ex-
posed to 5 WM IAPP in the presence and absence of 5 WM Congo
red (CR). Times refer to minutes after IAPP addition. The scale bar
(control monolayer) represents 100 Wm, and applies to all the im-
ages.
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and it is signi¢cant that transgenic animals with fully convinc-
ing pathological and behavioural ‘AD’ phenotypes have yet to
be generated. Despite this, it is generally accepted that AL
peptides, like hIAPP, interact with and disrupt the function
of cell membranes. Iversen et al. [25] discuss the strong cir-
cumstantial evidence linking AL proteins to a causative role in
AD, and in vitro these peptides also form Ca2-permeable ion
channels [17], similar to hIAPP. Prion proteins are also amy-
loidogenic, and bind to membranes [26]. Recombinant anti-
body antigen-binding fragments that inhibit prion propaga-
tion appear to act on cell surface prions [27], and it will be
interesting to discover whether the recently described anti-
prion pharmacotherapeutics of Korth et al. [28] act in a re-
lated manner.
The structural basis underlying the interactions of rifampi-
cin and Congo red with IAPP, leading to the modi¢cation of
its membrane activity, remains to be determined. The inhib-
itors appear to associate with IAPP to prevent or modify
membrane incorporation, but several molecular mechanisms
may be involved. Future studies using model membranes will
help to de¢ne these mechanisms, and may identify additional
compounds that also prevent (or reverse) IAPP-induced mem-
brane damage. Small molecule therapeutics may provide a
novel approach to disable membrane-active IAPP (or AL) in
NIDDM (or AD), irrespective of whether the fundamental
biological mechanism is related to defective molecular chap-
eroning or to other defects in protein processing in L cells or
neurones. Inhibitors of the membrane activity of IAPP may
also stabilise membrane-associated complexes, to facilitate de-
tailed structural analysis.
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